Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment: A ReaL World Observational Study

NCT07435922 is registered in ClinicalTrials.gov with Healthgen Biotechnology Corp. as lead sponsor.

NCT NCT07435922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07435922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment: A ReaL World Observational Study
Lead sponsor
Healthgen Biotechnology Corp.
Phase
Observational
Overall status
Not yet recruiting
Start date
February 24, 2026
Completion date
December 31, 2026
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoalbuminemia, hypovolemia